Motor complications, levodopa metabolism and progression of Parkinson's disease (Q37863681)

24 August 2017

1 reference

title

Motor complications, levodopa metabolism and progression of Parkinson's disease (English)

1 reference

24 August 2017

1 reference

1 reference

1

Thomas Müller

1 reference

PubMed ID

21480824

24 August 2017

language of work or name

English

0 references

publication date

12 April 2011

1 reference

Expert Opinion on Drug Metabolism & Toxicology

24 August 2017

1 reference

24 August 2017

7

1 reference

24 August 2017

7

1 reference

24 August 2017

847-855

1 reference

Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Pramipexole protects against H2O2-induced PC12 cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Dopamine autoreceptor function is lost in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Maladaptive striatal plasticity in L-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Molecular mechanisms of L-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Role of homocysteine in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Intracellular S-adenosylhomocysteine increased levels are associated with DNA hypomethylation in HUVEC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Occupation and risk of parkinsonism: a multicenter case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Levodopa availability improves with progression of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Levodopa in plasma correlates with body weight of parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Body weight influences pharmacokinetics of levodopa in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Clinical course in Parkinson's disease with elevated homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Glutathione and Parkinson's disease: is this the elephant in the room?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Mitochondria are the source of hydrogen peroxide for dynamic brain-cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Molecular mechanisms underlying levodopa-induced dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Disturbance of iron metabolism in Parkinson's disease -- ultrasonography as a biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Endothelial function markers in parkinsonian patients with hyperhomocysteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Effects of homocysteine on the dopaminergic system and behavior in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Neuropathy as a potential complication of levodopa use in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.575779

10.1517/17425255.2011.575779

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21480824